These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35688395)

  • 1. Novel therapeutic avenues for the study of chronic liver disease and regeneration: The foundation of the Iberoamerican Consortium for the study of liver Cirrhosis.
    Sanz-Garcia C; Nevzorova YA; Martínez-Naves E; Cubero FJ; ; Hionides-Gutierrez A; Sañudo JR; Enrich C; Rentero C; Sancho-Bru P; Macías-Rodriguez RU; Ruiz-Margain A; Kershenobich-Stalnikowitz D; Vargas NR; Muñoz AE; Nakaya HI
    Gastroenterol Hepatol; 2023 Apr; 46(4):322-328. PubMed ID: 35688395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH).
    Gallego-Durán R; Albillos A; Ampuero J; Arechederra M; Bañares R; Blas-García A; Berná G; Caparrós E; Delgado TC; Falcón-Pérez JM; Francés R; Fernández-Barrena MG; Graupera I; Iruzubieta P; Nevzorova YA; Nogueiras R; Macías RIR; Martín F; Sabio G; Soriano G; Vaquero J; Cubero FJ; Gracia-Sancho J
    Gastroenterol Hepatol; 2022 Nov; 45(9):724-734. PubMed ID: 35248669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.
    Marot A; Henrion J; Knebel JF; Moreno C; Deltenre P
    PLoS One; 2017; 12(10):e0186715. PubMed ID: 29077714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular Vesicles in NAFLD/ALD: From Pathobiology to Therapy.
    Hernández A; Arab JP; Reyes D; Lapitz A; Moshage H; Bañales JM; Arrese M
    Cells; 2020 Mar; 9(4):. PubMed ID: 32231001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist's View.
    Tiniakos DG; Maurício J; Reeves HL
    Adv Exp Med Biol; 2018; 1032():55-69. PubMed ID: 30362090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research progress of omics biomarkers for nonalcoholic fatty liver disease].
    Wang L; Liu XE; Zhuang H
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):604-608. PubMed ID: 34225440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alcoholic and Non-Alcoholic Liver Diseases: Promising Molecular Drug Targets and their Clinical Development.
    Thapa K; Grewal AS; Kanojia N; Rani L; Sharma N; Singh S
    Curr Drug Discov Technol; 2021; 18(3):333-353. PubMed ID: 31965945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014.
    Kim D; Cholankeril G; Li AA; Kim W; Tighe SP; Hameed B; Kwo PY; Harrison SA; Younossi ZM; Ahmed A
    Liver Int; 2019 Sep; 39(9):1661-1671. PubMed ID: 31081997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review.
    Singh S; Osna NA; Kharbanda KK
    World J Gastroenterol; 2017 Sep; 23(36):6549-6570. PubMed ID: 29085205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances.
    Lau JK; Zhang X; Yu J
    J Pathol; 2017 Jan; 241(1):36-44. PubMed ID: 27757953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse Model of Alcoholic Steatohepatitis.
    Bertola A
    Methods Mol Biol; 2020; 2164():145-157. PubMed ID: 32607891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Alcoholic liver disease - 2023].
    Pár A; Pár G
    Orv Hetil; 2023 Nov; 164(47):1846-1864. PubMed ID: 38007815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future therapy for non-alcoholic fatty liver disease.
    Issa D; Patel V; Sanyal AJ
    Liver Int; 2018 Feb; 38 Suppl 1():56-63. PubMed ID: 29427492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease.
    Vonghia L; Van Herck MA; Weyler J; Francque S
    Front Immunol; 2019; 10():563. PubMed ID: 30972062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different.
    Malnick SDH; Alin P; Somin M; Neuman MG
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease.
    Toshikuni N; Tsutsumi M; Arisawa T
    World J Gastroenterol; 2014 Jul; 20(26):8393-406. PubMed ID: 25024597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis, Early Diagnosis, and Therapeutic Management of Alcoholic Liver Disease.
    Kong LZ; Chandimali N; Han YH; Lee DH; Kim JS; Kim SU; Kim TD; Jeong DK; Sun HN; Lee DS; Kwon T
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31159489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical approach to non-alcoholic fatty liver disease in patients with diabetes.
    Tai FW; Syn WK; Alazawi W
    Diabet Med; 2015 Sep; 32(9):1121-33. PubMed ID: 25683343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hepatocellular damage and inflammation in various forms of alcoholic liver disease].
    Rodina AS; Shubina ME; Kurbatova IV; Topchieva LV; Dudanova OP
    Ter Arkh; 2021 Jan; 93(1):15-19. PubMed ID: 33720620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic liver disease and oxidative stress - a narrative review.
    Seen S
    Expert Rev Gastroenterol Hepatol; 2021 Sep; 15(9):1021-1035. PubMed ID: 34176419
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.